Cargando…
Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn’s disease
In 2018, the pan-Janus kinase (JAK) inhibitor tofacitinib was launched for the treatment of ulcerative colitis (UC). Although tofacitinib has proven efficacious in patients with active UC, it failed in patients with Crohn’s disease (CD). This finding strongly hints at a different contribution of JAK...
Autores principales: | Cordes, Friederike, Foell, Dirk, Ding, John Nik, Varga, Georg, Bettenworth, Dominik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403801/ https://www.ncbi.nlm.nih.gov/pubmed/32821070 http://dx.doi.org/10.3748/wjg.v26.i28.4055 |
Ejemplares similares
-
Peripheral Monocyte Functions and Activation in Patients with Quiescent Crohn’s Disease
por: Schwarzmaier, David, et al.
Publicado: (2013) -
Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer
por: Zundler, Sebastian, et al.
Publicado: (2016) -
Efficacy of JAK inhibitors in Ulcerative Colitis
por: Ferrante, Marc, et al.
Publicado: (2020) -
Plasma microRNA Profile Differentiates Crohn’s Colitis From Ulcerative
Colitis
por: Netz, Uri, et al.
Publicado: (2018) -
Differentially Expressed miRNAs in Ulcerative Colitis and Crohn’s Disease
por: Yarani, Reza, et al.
Publicado: (2022)